We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
+33.84%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
AUM
$299M
AUM Growth
+$15.4M
Cap. Flow
-$62.5M
Cap. Flow %
-20.91%
Top 10 Hldgs %
100%
Holding
4
New
Increased
Reduced
2
Closed

Top Buys

No buys this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 97.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MCRB icon
1
Seres Therapeutics
MCRB
$48.1M
$203M 68.04%
634,144
SYRS
2
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$47.2M 15.78%
320,444
-160,222
-33% -$30.1M
EDIT icon
3
Editas Medicine
EDIT
$399M
$40.2M 13.45%
1,674,435
-1,701,749
-50% -$32.4M
TTOO
4
DELISTED
T2 Biosystems, Inc
TTOO
$8.19M 2.74%
390

Similar funds

Flagship Pioneering's Q3 2017 Portfolio in Review

As of Q3 2017, Flagship Pioneering held 4 positions worth $299M, up 5.4% from $284M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering withdrew a net $62.5M in Q3 2017, reducing 2 holdings. Its largest reduction was Editas Medicine, cutting an estimated $32.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.

  • Flagship Pioneering's biggest Q3 2017 reduction was Editas Medicine, cutting an estimated $32.4M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $299M portfolio in Q3 2017.
  • Flagship Pioneering opened 0 new positions and closed 0 in Q3 2017.
  • Flagship Pioneering's portfolio value rose 5.4% quarter-over-quarter to $299M.

Based on Flagship Pioneering's 13F filing for Q3 2017, filed 3 Nov 2017.